Navigation Links
EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation
Date:9/22/2008

AMSTERDAM, September 22 /PRNewswire/ -- Kiadis Pharma announced today that its lead product ATIR(TM) has been granted orphan drug designation (ODD) by the European Medicines Agency (EMEA) for the prevention of acute Graft versus Host Disease (GvHD) following an allogeneic bone marrow transplantation.

"Following the orphan drug designation granted by the FDA for our lead product ATIR(TM), this is another important milestone in the development of ATIR(TM) as a novel approach which may enable a safe and potentially life-saving mismatched bone marrow transplantation as a treatment option for end-stage blood cancer patients" says Dr. Manja Bouman, Chief Executive Officer of Kiadis Pharma.

The EMEA's orphan drug designation is reserved for new therapies being developed to treat life-threatening or chronically debilitating diseases or conditions that are relatively rare in the European Union and for which no satisfactory therapy is available. The orphan drug designation provides for incentives to support research and development, exemption from user fees and a ten-year period of market exclusivity in the European Union after product approval.

For the complete press release please go to: http://www.kiadis.com/news

About Kiadis Pharma

Kiadis Pharma is an oncology focused pharmaceutical development company with three products in different phases of clinical development. The company develops products that offer novel treatment options for terminally ill cancer patients and address significant unmet medical needs. The key focus indication for Kiadis Pharma is limitations and complications of bone marrow transplantation procedures performed in blood cancer patients. Kiadis Pharma is headquartered in Amsterdam, The Netherlands with facilities in Groningen, The Netherlands and Montreal, Canada. For more information about Kiadis Pharma, please visit '/>"/>

SOURCE Kiadis Pharma
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Mirus Bio Awarded Grants & Contracts of Over $5 Million
2. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. NIH grants $750,000 to develop device to determine temperature of neonates brain
5. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
6. Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis
7. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
8. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
9. NASDAQ Panel Grants Merge Technologies Additional Time to Regain Compliance
10. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
11. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... -- Senomyx , Inc. (NASDAQ: SNMX ... discover, develop, and commercialize novel flavor ingredients, announced today ... Company,s Vice President, Biology and Gwen Rosenberg ... will present an overview of Senomyx,s technology and programs ... (7:25 a.m. Pacific Time) during the Citi 2013 Global ...
(Date:5/24/2013)... Canada (PRWEB) May 24, 2013 Many ... barriers, and uptake or efflux transporters at the blood-tissue ... be related to unbound fractions in the tissue rather ... of these disposition challenges is required to guide lead ... to identify any species-dependent variables that may impact the ...
(Date:5/24/2013)... Vestiage, Inc. (stock symbol "VEST") a ... research and development, sales and marketing of premium ... today that it is awarding exclusive Vestiage territories ... Reluma Skin Illuminating Facial Care. Qualified applicants can ... an email to info(at)vestiageinc(dot)com and putting RELUMA in ...
(Date:5/23/2013)... Die Übersetzungen wurden von PRNewswire ... der englischen Version handelt es sich um ... Teilnehmer einer groß angelegten Asthmaumfrage halten ihren Zustand für ... -Definition [1] als kontrolliert gelten können ... von vier Denkweisen zugeordnet werden können, die alle von ...
Breaking Biology Technology:SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CITI 2013 GLOBAL CONSUMER CONFERENCE 2DMPK for Targeted Tissue Delivery: Solutions for the Most Challenging Part of Outsourcing, New Life Science Webinar Hosted by Xtalks 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 2Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 3Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 4Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 6Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 7
... 8 Beckman Coulter, Inc. (NYSE: ... of products that simplify, automate, and innovate complex ... Coulter,s chairman, president and chief executive officer, will ... Lynch Healthcare Conference on Wednesday, May 13, 2009 ...
... Yongye Biotechnology,International, Inc. (OTC Bulletin Board: YGYB, ... distributor of plant and animal nutrient products ... that it closed a private placement,financing with ... of the same investors who participated in ...
... 8 PharmAthene, Inc. (NYSE Amex: PIP ... and chemical threats, announced a date change for its ... 2009 financial results will now be released on Friday, ... call to discuss its first quarter 2009 financial results. ...
Cached Biology Technology:Yongye Biotechnology International Raises $ 9.0 Million In Private Placement, Raises Guidance 2Yongye Biotechnology International Raises $ 9.0 Million In Private Placement, Raises Guidance 3
(Date:5/24/2013)... of 500 leading water scientists from around the world ... "in the short span of one or two generations, ... will be living under the handicap of severe pressure ... which there is no substitute. This handicap will be ... scientists bluntly pointed to chronic underlying problems led by ...
(Date:5/23/2013)... RICHLAND, Wash. Pacific Northwest National Laboratory honored ... and commercialization of intellectual property at PNNL,s annual ... , The Department of Energy national laboratory ... Year for his work developing battery materials that ... to the electrical grid, and reduce the time ...
(Date:5/23/2013)... suppresses lipid synthesis in the liver, UC Irvine endocrinologists ... liver diseases. , With this finding, Dr. Ellis ... in the field. Study results appear in the May ... , "The dogma in the steroid receptor field for ... the nucleus respond to steroid hormones by regulating genes ...
Breaking Biology News(10 mins):A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 2A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 3A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 4PNNL staff recognized for scientific accomplishments, moving technologies into the marketplace 2UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2
... cancer, including stomach, liver and colon, are far more common ... differences in lifestyle, such as diet and smoking, may account ... are rooted in basic biological differences between men and women. ... shows that treating male mice with estrogen dramatically lowers their ...
... giant seaweeds, are spreading fast, with harmful effects on ... the Mediterranean seabed. Some native species, such as sea ... invasion, but only during its early stages, or when ... carried out a study to look at the ability ...
... If genetically modified Atlantic salmon were to escape ... their genes into the wild, Canadian researchers have found. ... the potential reproductive implications of GM salmon as they ... of growth-enhancing transgenic technologies has long been of interest ...
Cached Biology News:Study explains why men are at higher risk for stomach cancer 2Study explains why men are at higher risk for stomach cancer 3Sea urchins cannot control invasive seaweeds 2First study into GM Atlantic salmon mating reveals danger of escape to wild gene pool 2
The Captivate Disposable Sample Chamber is designed for use with the Captivate magnetic yoke assembly (C-24700) and can be used with our Captivate ferrofluid conjugates (C-21473 C-21474 C-21476) or ...
MOUSE ANTI HUMAN MOC31:AZIDE FREE...
... mycobacteria in Complete Freund's adjuvant attract macrophages ... which enhances the immuneresponse. For this reason, ... the initial injections; Incomplete Freund's adjuvant is ... in saline) are typically mixed with an ...
HiTrap Streptavidin HP, 5 x 1 ml. Category: Chromatography Systems & Accessories, Systems....
Biology Products: